Taysha Gene Therapies Total Non-Operating Income/Expense 2020-2024 | TSHA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Taysha Gene Therapies total non-operating income/expense from 2020 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.

Taysha Gene Therapies Total Non-Operating Income/Expense 2020-2024 | TSHA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Taysha Gene Therapies total non-operating income/expense from 2020 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
Teva Pharmaceutical Industries (TEVA)	$20.1B
Dr Reddy's Laboratories (RDY)	$13.1B
BridgeBio Pharma (BBIO)	$5B
Bausch Health Cos (BHC)	$3B
Amphastar Pharmaceuticals (AMPH)	$2.4B
Supernus Pharmaceuticals (SUPN)	$1.8B
Personalis (PSNL)	$315M
Assembly Biosciences (ASMB)	$117M
Acasti Pharma (ACST)	$28M
Sol-Gel Technologies (SLGL)	$20M
Evoke Pharma (EVOK)	$4M
Teligent (TLGT)	$0M